中国化学(601117.SH)2019年净利预增50%到70%
格隆汇1月17日丨中国化学(601117.SH)发表2019年年度业绩预告,预计2019年度实现归属于上市公司股东的净利润较上年同期(19.32亿元)增加50%到70%。归属于上市公司股东的扣除非经常性损益的净利润较上年同期(17.22亿元)增加60%到80%。
019年公司注重战略引领与战略执行,坚决贯彻落实国家发展战略,不断优化经营布局,全面推进生产经营管理组织模式改革,压减三级企业数量,精细化管理取得实效。公司积极把握市场机遇,各项业务发展良好,海外市场开拓取得历史性突破,主要业务利润水平相比上年同期有较大幅度增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.